Related references
Note: Only part of the references are listed.A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction
F. Klevebro et al.
ANNALS OF ONCOLOGY (2016)
What to do after R1-resection of adenocarcinomas of the esophagogastric junction?
Ralf Gertler et al.
JOURNAL OF SURGICAL ONCOLOGY (2016)
Comparison of dosimetric parameters and toxicity in esophageal cancer patients undergoing 3D conformal radiotherapy or VMAT
Stefan Muench et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2016)
Tumor Stage After Neoadjuvant Chemotherapy Determines Survival After Surgery for Adenocarcinoma of the Esophagus and Esophagogastric Junction
Andrew R. Davies et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Patterns of Recurrence After Surgery Alone Versus Preoperative Chemoradiotherapy and Surgery in the CROSS Trials
Vera Oppedijk et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Systematic review and meta-analysis of the influence of circumferential resection margin involvement on survival in patients with operable oesophageal cancer
D. S. Y. Chan et al.
BRITISH JOURNAL OF SURGERY (2013)
Neoadjuvant therapy with weekly docetaxel and cisplatin, 5-fluorouracil continuous infusion, and concurrent radiotherapy in patients with locally advanced esophageal cancer produced a high percentage of long-lasting pathological complete response A phase 2 study
Felice Pasini et al.
CANCER (2013)
Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)†
P. C. Thuss-Patience et al.
ANNALS OF ONCOLOGY (2012)
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
P. van Hagen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
Marc Ychou et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Pathologic Response after Neoadjuvant Therapy is the Major Determinant of Survival in Patients with Esophageal Cancer
Kenneth L. Meredith et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Phase I/II Trial of Preoperative Oxaliplatin, Docetaxel, and Capecitabine With Concurrent Radiation Therapy in Localized Carcinoma of the Esophagus or Gastroesophageal Junction
David R. Spigel et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Complete Pathologic Response After Neoadjuvant Chemoradiotherapy for Esophageal Cancer Is Associated With Enhanced Survival
James M. Donahue et al.
ANNALS OF THORACIC SURGERY (2009)
Influence of circumferential resection margin on prognosis in distal esophageal and gastroesophageal cancer approached through the transhiatal route
J. J. G. Scheepers et al.
DISEASES OF THE ESOPHAGUS (2009)
Long-Term Results of a Randomized Trial of Surgery With or Without Preoperative Chemotherapy in Esophageal Cancer
William H. Allum et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Comparison of Preoperative Chemotherapy Compared With Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Esophagogastric Junction
Michael Stahl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy cancer and adenocarcinoma of in advanced gastric the gastroesophageal junction: results of a phase II trial
S. Lorenzen et al.
ANNALS OF ONCOLOGY (2007)
Adenocarcinoma of the gastroesophageal junction - Influence of esophageal resection margin and operative approach on outcome
Andrew P. Barbour et al.
ANNALS OF SURGERY (2007)
Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial
BH Burmeister et al.
LANCET ONCOLOGY (2005)
Share Paper
